Novartis AG (NVS)
| Market Cap | 284.82B +28.1% |
| Revenue (ttm) | 56.58B +6.3% |
| Net Income | 13.53B +5.2% |
| EPS | 6.98 +9.5% |
| Shares Out | 1.91B |
| PE Ratio | 21.04 |
| Forward PE | 16.61 |
| Dividend | $3.08 (2.06%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 1,271,464 |
| Open | 148.23 |
| Previous Close | 148.16 |
| Day's Range | 148.16 - 150.33 |
| 52-Week Range | 104.93 - 170.46 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 144.00 (-3.84%) |
| Earnings Date | Apr 28, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $144.0, which is a decrease of -3.84% from the latest price.
News
Isomorphic Labs' $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
On Tuesday, Isomorphic Labs, the Alphabet-founded firm that uses AI to accelerate drug development, said that it had raised $2.1 billion from investors led by Thrive Capital. That's a boatload of cash...
AVDE, SHEL, HSBC, NVS: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Avantis International Equity ETF (Symbol: AVDE) where we have detected...
Novartis seeks to deepen India innovation play
Swiss pharma major Novartis is sharpening its strategy in India as a pure-play innovator across core therapy segments, including cardiovascular, oncology, and immunology. The company is moving further...
Novartis breaks ground on radioligand therapy manufacturing site in Texas
Novartis (NVS) broke ground on its new 46,000 sq. ft radioligand therapy manufacturing site in Denton, Texas, the latest milestone in its broader $23B investment in U.S. manufacturing and research.
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest mile...
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.
Novartis to cut 220 jobs as it closes German site
Swiss drugmaker Novartis said on Tuesday that it is set to cut around 220 jobs in Germany as part of the planned closure of a production site by the end of 2028.
‘I’d lost my identity.’ How this exec recovered from redundancy
A new coach, hypnotist and Hollywood movie helped Allison Rossiter tackle one of her biggest fears. Now, the Novartis president shares how they can help you too.
November 20th Options Now Available For Novartis (NVS)
Investors in Novartis (Symbol: NVS) saw new options become available today, for the November 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the t...
Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100
Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100
Novartis (NVS) Expands Manufacturing with New Facility in North Carolina
Novartis (NVS) Expands Manufacturing with New Facility in North Carolina
Novartis announces plans to add new facility in Morrisville, North Carolina
Novartis (NVS) announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient, API, manufacturing for solid dosage tablets, capsules and RNA therapeu...
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
The IgAN market is growing due to rising prevalence, improved diagnostics, novel immunotherapies, ongoing clinical trials of therapies such as Zigakibart (Novartis), Sefaxersen (F. Hoffmann-La Roche/I...
Noteworthy ETF Inflows: AVDE, SHEL, HSBC, NVS
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Avantis International Equity ETF (Symbol: AVDE) where we have detected...
UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giant...
Novartis AG (NVS) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Core Income ...
Novartis AG (NVS) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Core Income Challenges
Q1 2026 Novartis AG Earnings Call Transcript
Q1 2026 Novartis AG Earnings Call Transcript
Novartis Expands R&D Spending Up To $70 Million Monthly After Avidity Deal
Novartis Expands R&D Spending Up To $70 Million Monthly After Avidity Deal
Novartis CEO warns of reality of Trump's drug pricing policy
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
Novartis CEO warns of reality of Trump's drug pricing policy
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
Novartis CEO on Q1 earnings miss
Novartis CEO Vas Narasimhan joins 'Money Movers' to discuss the company's latest earnings report, policies around drug pricing, and more.
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Novartis CEO Vas Narasimhan joins 'Money Movers' to discuss the company's latest earnings report, policies around drug pricing, and more.
Novartis Stock Declines After Q1 Revenue Misses Expectations
Novartis Stock Declines After Q1 Revenue Misses Expectations
Market Update: Microsoft (MSFT), Novartis (NVS), Coca-Cola (KO) Performance Amidst Economic Concerns
Market Update: Microsoft (MSFT), Novartis (NVS), Coca-Cola (KO) Performance Amidst Economic Concerns
Novartis Dips As Generics Take A Bite Out Of Its First-Quarter Sales
Novartis stock fell early Tuesday on lighter-than-expected first-quarter earnings and sales amid U.S. generic erosion.